MDR | Jotup

Volta Medical Receives CE Mark for AF-Xplorer™ Decision support solution to Simplify Complex Atrial Fibrillation Procedures

Retrieved on:

Wednesday, February 28, 2024

CE, Artificial intelligence, Randomized controlled trial, MDR, FDA, Atrial tachycardia, Food, Growth, Database, E-GMS, European, Atrial fibrillation, Food and Drug Administration, Patient, Deep learning, Tailor, Medical device

This major step will enable sales and distribution of the new product in the European Union (EU).

Key Points:

This major step will enable sales and distribution of the new product in the European Union (EU).
“We are pleased that Volta’s AF-Xplorer™ is now available in the EU to assist electrophysiologists in the treatment of patients with atrial fibrillation,” said Theophile Mohr-Durdez, Volta Medical CEO and co-founder.
This methodology facilitates a standardized approach to pinpointing what is known as spatiotemporal dispersed EGMs, a suspected source of AF.
Volta’s AF-Xplorer™ also received U.S. Food and Drug Administration (FDA) clearance in January 2023 for the real-time manual or automatic annotation of spatiotemporal dispersions during AF and atrial tachycardia (AT) procedures.

Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

Retrieved on:

Monday, February 26, 2024

Therapy, Infection, MDR, Spero, Conference

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA.

Key Points:

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA.
Details are as follows:
The webcasts for this event may also be accessed through Spero Therapeutics’ website ( www.sperotherapeutics.com ) on the “Events and Presentations” page under the “Connect” tab.
Replays will be available on the website following the conclusion of each event.

iRhythm Technologies Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Thursday, February 22, 2024

SAN, MDR, Investment, Physician, Growth, IRTC, American College, Aircraft, Patient, Video game

Revenue for the three months ended December 31, 2023, increased 17.7% to $132.5 million, from $112.6 million during the same period in 2022.

Key Points:

Revenue for the three months ended December 31, 2023, increased 17.7% to $132.5 million, from $112.6 million during the same period in 2022.
Gross profit for the fourth quarter of 2023 was $87.4 million, up from $78.7 million during the same period in 2022, while gross margins were 66.0% as compared to 69.9% during the same period in 2022.
Operating expenses for the fourth quarter of 2023 were $126.6 million, compared to $99.4 million for the same period in 2022 and $110.1 million in Q3 2023.
Revenue for the year ended December 31, 2023, increased 19.9% to $492.7 million, from $410.9 million in 2022.

Sophos Expands Commitment to the Channel with New Dedicated Partner Care Offering

Retrieved on:

Wednesday, February 21, 2024

Managed services, Intelligence, MDR, NFR, News, Small business, Veeam, XDR, 24/7 service, Private investigator

OXFORD, United Kingdom, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sophos , a global leader in innovating and delivering cybersecurity as a service, is expanding its commitment to the channel with the addition of Partner Care, a new offering in its global partner program that features a dedicated, 24x7 team of Sophos experts who handle non-sales related questions and operational support.

Key Points:

OXFORD, United Kingdom, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sophos , a global leader in innovating and delivering cybersecurity as a service, is expanding its commitment to the channel with the addition of Partner Care, a new offering in its global partner program that features a dedicated, 24x7 team of Sophos experts who handle non-sales related questions and operational support.
“Being busy with administration can consume a lot of time and cost, so the idea that Sophos now has a focused Partner Care program and dedicated team to handle it is unbelievably beneficial,” said Richard Wenger, account executive, Point Broadband LLC, a Sophos channel partner based in Alabama.
This Sophos Partner Care program is essential to my business.”
In addition to Partner Care, Sophos is offering several enhancements to its global partner program, including an additional 5% reward on top of a deal registration discount for partners selling Sophos Managed Detection and Response (MDR)1.
To help streamline varying technologies within customers’ environments, Sophos also recently added a Veeam integration to its Sophos MDR and XDR solutions.

Bitdefender Launches Powerful Cloud Security Posture Management Solution

Retrieved on:

Thursday, March 7, 2024

Bitdefender, a global cybersecurity leader, today unveiled GravityZone CSPM+ , a powerful Cloud Security Posture Management (CSPM) solution for monitoring and managing configurations of cloud infrastructures including Amazon Web Services (AWS), Google Cloud Platform (GCP), Microsoft Azure and others.

Key Points:

Bitdefender, a global cybersecurity leader, today unveiled GravityZone CSPM+ , a powerful Cloud Security Posture Management (CSPM) solution for monitoring and managing configurations of cloud infrastructures including Amazon Web Services (AWS), Google Cloud Platform (GCP), Microsoft Azure and others.
“GravityZone CSPM+ extends security, configuration management, and IAM capabilities across cloud infrastructures on a single platform - empowering businesses to proactively mitigate risks and strengthen overall security posture.
Additionally, GravityZone includes industry leading endpoint protection , container security with run-time support for containers and Linux kernel module independence, and security for servers , hypervisors, and virtualized environments – a true Cloud Native Security solution.
Genetics testing company NalaGenetics stated, “Right from the start, Bitdefender CSPM+ helped bridge the gap in terms of cloud infrastructure and security expertise.

Deepwatch Unlocks New Capabilities and Increased Flexibility with its Open Security Data Architecture

Retrieved on:

Tuesday, March 5, 2024

Data Management, Security, Technology, Software, Networks, Internet, Sentinel, CSMA, Architecture, CrowdStrike, MDR, Mining, SOAR, Future, EDR, Synthetic media, SIEM, OSDA, XDR

“Deepwatch is providing an open, agnostic approach to cyber resilience, leveraging existing customer investments,” said Charlie Thomas, Deepwatch CEO.

Key Points:

“Deepwatch is providing an open, agnostic approach to cyber resilience, leveraging existing customer investments,” said Charlie Thomas, Deepwatch CEO.
Deepwatch will deliver its Open Security Data Architecture (OSDA) through the next generation of the Deepwatch platform with support for Splunk today, Microsoft Sentinel in April 2024, and CrowdStrike shortly after.
Microsoft Sentinel support will be the first of many data sources followed by other sources (Endpoints, EDR, SIEMs, XDR, data lakes, and cloud) that Deepwatch will support to unlock new capabilities and increased data flexibility.
Learn more about the Deepwatch Open Security Data Architecture and its commitment to protecting enterprises from the latest adversaries.

CPAC Enhances Award-Winning I.T. Services With Cynet’s All-In-One Cybersecurity Solution

Retrieved on:

Tuesday, March 5, 2024

CPAC will leverage Cynet’s all-in-one cybersecurity solution to rapidly unlock powerful advantages for current and future clients, including:

Key Points:

CPAC will leverage Cynet’s all-in-one cybersecurity solution to rapidly unlock powerful advantages for current and future clients, including:
Total visibility and protection: Cynet’s all-in-one solution unifies a full suite of security capabilities, including prevention, detection, correlation, investigation and response.
“Every member of the Cynet team is motivated by the positive impact we see partners like CPAC amplifying with Cynet’s all-in-one cybersecurity solution,” says Eyal Gruner, Co-Founder & CEO, Cynet.
By unifying a full security suite of capabilities on a single, easy-to-use solution, Cynet’s all-in-one cybersecurity solution generates savings for our partners to invest in their own business expansion.
Now, enabled by Cynet, CPAC clients are empowered to secure success with the same cutting-edge capabilities as multinational corporations with extensive I.T.

CrowdStrike Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Retrieved on:

Tuesday, March 5, 2024

Data Management, Security, Technology, Mobile, Wireless, Software, Networks, Internet, Cloud, Ability, Acquisition, Innovation, CrowdStrike, Scale (music), Completeness, AI, Magic, MDR, Growth, ARR, Customer, GAAP, Overalls, SIEM, Strategy, XDR, IRAP, Investment, Partnership

CrowdStrike Holdings, Inc. (Nasdaq: CRWD), a global cybersecurity leader that provides cloud-delivered protection of endpoints, cloud workloads, identity and data, today announced financial results for the fourth quarter and fiscal year 2024, ended January 31, 2024.

Key Points:

CrowdStrike Holdings, Inc. (Nasdaq: CRWD), a global cybersecurity leader that provides cloud-delivered protection of endpoints, cloud workloads, identity and data, today announced financial results for the fourth quarter and fiscal year 2024, ended January 31, 2024.
Revenue: Total revenue was $845.3 million, a 33% increase, compared to $637.4 million in the fourth quarter of fiscal 2023.
Net Income/Loss Attributable to CrowdStrike: GAAP net income attributable to CrowdStrike was $53.7 million, compared to a loss of $47.5 million in the fourth quarter of fiscal 2023.
Non-GAAP net income attributable to CrowdStrike was $236.2 million, compared to $111.6 million in the fourth quarter of fiscal 2023.

Bitdefender Launches Powerful Endpoint Protection and Security Service Solutions Tailored for Managed Service Providers

Retrieved on:

Tuesday, March 5, 2024

Bitdefender GravityZone Cloud MSP Security Solutions is powered by the GravityZone Platform , a unified security and risk analytics platform that provides advanced endpoint protection including endpoint detection and response (EDR), extended detection and response (XDR) and cloud security for physical, virtual, and multi-cloud environments.

Key Points:

Bitdefender GravityZone Cloud MSP Security Solutions is powered by the GravityZone Platform , a unified security and risk analytics platform that provides advanced endpoint protection including endpoint detection and response (EDR), extended detection and response (XDR) and cloud security for physical, virtual, and multi-cloud environments.
GravityZone Cloud MSP Security Solutions is offered in multiple tiers including Secure, Secure Plus, and Secure Extra - each providing best-in-class security protection yet tailored to fit an MSP customers’ specific needs, requirements (including compliance) and budgets.
Bitdefender is renowned for its excellence in threat protection consistently ranking number one in independent third-party tests including AV-Comparatives and MITRE ATT&CK .
MSP partner Blaze Networks touts Bitdefender endpoint protection and MDR capabilities stating, “Bitdefender’s MDR offering gives me peace of mind.

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Retrieved on:

Tuesday, March 5, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.

Key Points:

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.
“The latest findings across our HIV pipeline showcase the potential of multiple candidates to help transform HIV management,” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences.
It is estimated that up to 10% of people with HIV take a complex treatment regimen, defined as 2 or more pills each day.
Results showed that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study.